Molecular hydrogen-rhodiola as an adjuvant therapy for ischemic stroke in internal carotid artery occlusion: A case report.
Feng-Hao Chang, Jeng-Wei Lu, Chun-Chih Hu, Wun-Long Jheng, Shuk-Man Ka, Shinn-Zong Lin, Dueng-Yuan Hueng, Yueh-Feng Sung, Ying-Hsuan Tsai, Jou-I Tu, Yi-Jung Ho, Kuang-Yih Wang, Feng-Cheng Liu · Open medicine (Warsaw, Poland) · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In a patient with ICA occlusion, this case highlights the potential of molecular hydrogen-rhodiola therapy as a safe and effective adjunctive treatment for ischemic stroke due to ICA occlusion. These findings add human evidence supporting molecular hydrogen's therapeutic potential for stroke recovery.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in a patient with ICA occlusion. This case highlights the potential of molecular hydrogen-rhodiola therapy as a safe and effective adjunctive treatment for ischemic stroke due to ICA occlusion.
What the Researchers Studied
The researchers studied a patient with ICA occlusion.
What Effects Did Molecular Hydrogen Have?
Although natural recovery processes and concurrent medical interventions undoubtedly contributed to this outcome, the temporal correlation between hydrogen administration, immunological changes, and accelerated neurological recovery supports a possible therapeutic contribution from hydrogen-rhodiola supplementation. Through these actions, hydrogen may indirectly support the proliferation and function of regulatory immune cells while mitigating the deleterious effects of oxidative stress. These factors represent significant potential confounders, making it difficult to attribute the observed clinical improvements solely to the adjuvant hydrogen and Rhodiola therapy. This case highlights the potential of molecular hydrogen-rhodiola therapy as a safe and effective adjunctive treatment for ischemic stroke due to ICA occlusion.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for stroke recovery and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a case report. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as case report with human clinical evidence. The research population or model was a patient with ICA occlusion.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.